MLD is please to announce that Dr. Shawn Ritchie, CEO and Chief Scientific Officer, will be presenting at the World Orphan Drug Congress in Oxon Hill, Maryland, April 12, 2019. The talk is titled "Synthetic plasmalogen precursor PPI-1040 for the treatment of Rhizomelic Chondrodysplasia Punctata (RCDP) and other rare pediatric peroxisomal disorders." More information about the conference can be found here.
MLD presenting on RCDP at the World Orphan Drug Congress, 2019.
Previous
Previous
MLD granted second Pre-IND meeting with the FDA for PPI-1040 and treatment of RCDP
Next
Next